Reports Q2 (Jun) loss of $0.06 per share, $0.39 better than
the Capital IQ Consensus Estimate of ($0.45); revenues were unchanged from the year-ago period at $6.3 mln.
Anticipated 2014 Milestones:
- Total revenue is primarily comprised of collaborative revenue from bluebird bio's collaboration with Celgene Corporation (CELG).
- Present further clinical results in beta-thalassemia major from HGB-205 and Northstar Studies in late 2014
- Transplant first sickle cell disease patient with LentiGlobin product candidate
"The second quarter of 2014 has been very productive for bluebird bio," said Nick Leschly, chief bluebird. "In June, we presented some very encouraging clinical data on our LentiGlobin product candidate for beta-thalassemia at the EHA conference in Milan, Italy. Also in June, we broadened our technology platform through the acquisition of Pregenen, a gene editing company, and in July we completed a $110 million stock offering, strengthening our balance sheet and allowing us to drive forward all our programs."